🔍

APOLLOHOSP - Apollo Hospitals

📊 NSE: APOLLOHOSP 🏢 Healthcare 📅 Last Updated: 12/13/2025 18:25

📢 Recent Corporate Announcements

Apollo Hospitals Receives NCLT Order to Convene Meetings for Composite Scheme on May 27, 2026

🟡 NEUTRAL ⭐ 7/10

M&A 📅 18 Apr 2026, 10:36 AM

Apollo Hospitals Enterprise Limited (AHEL) has received an order from the NCLT Chennai regarding its composite scheme of arrangement involving Apollo Healthco, Keimed, and Apollo Healthtech. The tribunal has scheduled the meeting for equity shareholders and unsecured creditors of AHEL for May 27, 2026. Although the company sought to dispense with the secured creditors' meeting citing 90.96% consent, the NCLT has directed that the meeting must proceed on May 27, 2026. This procedural step is crucial for the proposed restructuring of the group's pharmacy and digital health businesses.

NCLT has fixed May 27, 2026, at 2:30 PM for the meeting of Apollo Hospitals' equity shareholders.
The meeting for unsecured creditors of Apollo Hospitals is scheduled for May 27, 2026, at 11:00 AM.
Tribunal rejected the request to dispense with the secured creditors' meeting despite 90.96% consent already obtained.
Meetings for other involved entities (Transferor Companies) are scheduled for May 26, 2026.
The scheme remains subject to final approvals from shareholders, creditors, and regulatory authorities.

💡 Investors should track the outcome of the shareholder meeting on May 27, 2026, as this restructuring is a key milestone for the company's long-term strategy. No immediate portfolio action is required until the voting results and subsequent regulatory clearances are finalized.

Apollo Hospitals Acquires Remaining Stake in AHLL for Rs 18.69 Cr; Becomes 100% Subsidiary

🟢 POSITIVE ⭐ 7/10

M&A 📅 10 Apr 2026, 06:32 PM

Apollo Hospitals Enterprise Limited has completed the acquisition of the remaining stake in its subsidiary, Apollo Health and Lifestyle Limited (AHLL). The company purchased 775,744 equity shares from individual shareholders at a price of Rs 241 per share, amounting to a total consideration of Rs 18.69 crores. This transaction follows previous acquisitions from IFC and IFC EAF, which had already increased the stake to 99.42%. With this final purchase, AHLL has now become a 100% wholly-owned subsidiary of Apollo Hospitals.

Acquired 775,744 equity shares of Apollo Health and Lifestyle Limited (AHLL) from individual shareholders.
The acquisition was executed at a price of Rs 241 per share, totaling Rs 18.69 crores.
Company's shareholding in AHLL increased from 99.42% to 100% following this transaction.
AHLL is now a wholly-owned subsidiary, simplifying the corporate structure for the retail healthcare business.

💡 Investors should view this as a positive consolidation move that gives Apollo Hospitals full control over its primary care and diagnostic business. No immediate action is required, but it reinforces the company's focus on its retail health growth engine.

Apollo Hospitals Receives NCLT Order for Composite Scheme of Arrangement

🟢 POSITIVE ⭐ 9/10

M&A 📅 10 Apr 2026, 03:25 PM

Apollo Hospitals Enterprise Limited (AHEL) has received a certified order from the NCLT Chennai Bench regarding its composite scheme of arrangement. The scheme involves the restructuring of Apollo Healthco, Keimed Private Limited, and Apollo Healthtech to streamline the pharmacy distribution and digital health business. The Tribunal has directed AHEL to convene meetings of its equity shareholders and creditors to seek approval for the proposed arrangement. This is a critical step in the company's long-term strategy to consolidate its pharmacy supply chain and digital platform.

NCLT order dated March 26, 2026, received by the company on April 9, 2026, regarding the composite scheme.
The arrangement involves Apollo Hospitals (Demerged Co), Apollo Healthco (Transferor 1), Keimed (Transferor 2), and Apollo Healthtech (Resultant Co).
Tribunal directed the convening of a meeting for AHEL equity shareholders via VC/OAVM to vote on the scheme.
Meetings for equity shareholders of Keimed Private Limited and Apollo Healthtech Limited have been dispensed with by the Tribunal.
The restructuring aims to integrate the wholesale distribution business of Keimed with the pharmacy platform of Apollo Healthco.

💡 Investors should vote in favor of the scheme as it is expected to simplify the corporate structure and unlock value in the pharmacy and digital health segments. Monitor the upcoming shareholder meeting date and subsequent voting results for further clarity on the execution timeline.

Apollo Hospitals Gets NCLT Approval to Convene Meetings for Composite Scheme of Arrangement

🟢 POSITIVE ⭐ 8/10

M&A 📅 03 Apr 2026, 05:03 PM

Apollo Hospitals Enterprise Limited (APOLLOHOSP) has received an order from the NCLT Chennai Bench regarding its composite scheme of arrangement involving Apollo Healthco, Keimed, and Apollo Healthtech. The Tribunal has directed the company to convene meetings for its equity shareholders, secured creditors, and unsecured creditors to seek approval for the restructuring. As of June 2025, the company reported a paid-up share capital of ₹71.89 crore consisting of 14.37 crore equity shares. This regulatory milestone is a key step in the company's plan to consolidate its pharmacy distribution and digital health platforms.

NCLT Chennai Bench allowed the application for the composite scheme of arrangement in an order dated March 26, 2026.
The Tribunal directed the convening of meetings for equity shareholders and creditors of Apollo Hospitals to vote on the scheme.
Meetings for shareholders of Apollo Healthco, Keimed, and Apollo Healthtech have been dispensed with by the Tribunal.
The scheme involves the demerger and consolidation of health-tech and pharmacy distribution assets into a resultant company.
Final implementation is subject to the approval of shareholders, creditors, and a final sanction order from the NCLT.

💡 Investors should monitor the outcomes of the upcoming shareholder and creditor meetings as this restructuring is intended to unlock value in the digital health segment. No immediate action is required, but the progress indicates the consolidation plan is on track.

Apollo Hospitals Subsidiary Acquires 100% of Apollo Consumer Products for ₹9 Lakhs

🟡 NEUTRAL ⭐ 4/10

M&A 📅 31 Mar 2026, 04:39 PM

Apollo Healthco Limited, a material subsidiary of Apollo Hospitals, has acquired a 100% stake in the newly incorporated Apollo Consumer Products Limited for ₹9.00 lakhs. The target entity will engage in the trading and distribution of FMCG, personal care, and wellness products through various channels including D2C and e-commerce. This move signifies Apollo's intent to broaden its consumer goods portfolio and leverage its existing supply chain infrastructure. Although the financial impact is currently negligible, it marks a strategic entry into the fast-moving consumer goods market.

Acquisition of 100% equity (90,000 shares) for a total consideration of ₹9.00 lakhs.
Target entity Apollo Consumer Products was incorporated on March 11, 2026, and is yet to commence operations.
The business will focus on FMCG, personal care, and wellness products via physical and digital platforms.
Apollo Healthco Limited, the acquirer, is a 78.88% subsidiary of Apollo Hospitals Enterprise Limited.

💡 No immediate action is required as the transaction size is very small relative to the company's market cap. Investors should track the scaling of this FMCG business within the Apollo Healthco ecosystem over the medium term.

Apollo Hospitals Announces Trading Window Closure from April 1, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 24 Mar 2026, 02:40 PM

Apollo Hospitals Enterprise Limited has informed the stock exchanges that its trading window will be closed starting April 1, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, for the purpose of considering audited financial results for the quarter and year ending March 31, 2026. The window will remain closed for all directors, designated employees, and insiders until 48 hours after the financial results are declared. The specific date of the board meeting to approve these results will be communicated at a later time.

Trading window closure effective from Wednesday, April 1, 2026.
Closure pertains to the audited financial results for the quarter and year ending March 31, 2026.
The window will reopen 48 hours after the announcement of the financial results to the exchanges.
Restriction applies to all directors, designated employees, and insiders as per the Company's Code of Conduct.

💡 This is a routine regulatory announcement with no impact on business fundamentals. Investors should monitor for the upcoming announcement of the board meeting date to assess the company's year-end financial performance.

Apollo Hospitals Completes 30.58% Stake Buy in AHLL for Rs 12,540.68 Million

🟢 POSITIVE ⭐ 8/10

M&A 📅 23 Mar 2026, 12:32 PM

Apollo Hospitals Enterprise Limited has successfully completed the acquisition of a 30.58% equity stake in its subsidiary, Apollo Health and Lifestyle Limited (AHLL). The stake was acquired from International Finance Corporation (IFC) and IFC EAF for a total consideration of Rs 12,540.68 million. Following this transaction, Apollo Hospitals' effective shareholding in AHLL has increased significantly to 99.42%. This move consolidates the company's control over its retail healthcare and primary care business segments.

Acquisition of 41,650,638 equity shares representing a 30.58% stake in AHLL.
Total purchase consideration of Rs 12,540.68 million paid to IFC and IFC EAF.
Effective shareholding in the subsidiary AHLL increased to 99.42%.
Transaction completed following necessary approval from the Competition Commission of India (CCI).
Consolidates ownership in the retail healthcare vertical including clinics and diagnostics.

💡 This consolidation of ownership in a key growth subsidiary is a positive long-term move; investors should monitor AHLL's contribution to the consolidated bottom line. The stock may see positive sentiment as the company simplifies its corporate structure and gains full control over AHLL's cash flows.

Apollo Hospitals Releases Q3 FY26 Earnings Call Transcript

🟡 NEUTRAL ⭐ 4/10

EARNINGS 📅 14 Feb 2026, 12:24 PM

Apollo Hospitals Enterprise Limited has officially released the transcript of its earnings conference call held on February 11, 2026. The transcript covers the company's unaudited financial performance for the third quarter and the nine-month period ending December 31, 2025. This document provides detailed management commentary and responses to institutional investor queries regarding operational metrics and future strategy. It is a standard regulatory disclosure following the announcement of quarterly results.

Transcript pertains to the earnings call conducted on February 11, 2026.
Covers financial performance for the nine-month period ended December 31, 2025.
Disclosure made in compliance with SEBI Listing Obligations and Disclosure Requirements.
Provides management insights into hospital segment performance and pharmacy business growth.
The full document is accessible via the company's official investor relations portal.

💡 Investors should review the transcript to understand management's guidance on bed occupancy, ARPOB trends, and the timeline for profitability in the digital health segment.

Apollo Hospitals Releases Q3 FY26 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 12 Feb 2026, 09:44 AM

Apollo Hospitals Enterprise Limited has officially released the audio recording of its analyst call held for the financial results of Q3 and 9M FY26. The recording covers management's discussion on performance for the period ended December 31, 2025. This disclosure is a standard regulatory requirement under SEBI (LODR) Regulations to ensure all investors have access to the same information. The link is now available on the company's website for public review.

Audio recording of the Q3 FY26 analyst call is now accessible via the company's website.
The call discussed financial results for the three and nine-month periods ended December 31, 2025.
Disclosure made in compliance with Regulations 30 and 46(2) of SEBI LODR.
Official filing date recorded as February 12, 2026.

💡 Investors should listen to the recording to understand management's commentary on occupancy levels, ARPOB trends, and the growth trajectory of the Apollo 24/7 digital platform. This is a routine update and does not require immediate portfolio changes.

Apollo Hospitals Q3 FY26: Consolidated PAT Surges 170% YoY to ₹5,023 Million

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 10 Feb 2026, 06:32 PM

Apollo Hospitals Enterprise Limited reported a robust performance for Q3 FY26, with consolidated revenue growing 17% YoY to ₹64,774 million. The company's bottom line saw a massive jump, with PAT increasing 170% YoY to ₹5,023 million, driven by strong operational performance across all business verticals. The core Healthcare Services segment maintained healthy EBITDA margins of 24.8%, while the Apollo HealthCo and AHLL segments both recorded 20% revenue growth, signaling strong momentum in digital health and retail clinics.

Consolidated Revenue increased by 17% YoY to ₹64,774 million in Q3 FY26.
Consolidated PAT witnessed a significant 170% YoY surge, reaching ₹5,023 million.
Healthcare Services (Hospitals) reported an EBITDA margin of 24.8% with 67% occupancy.
Apollo HealthCo (Digital & Pharmacy) revenue grew 20% YoY to ₹28,274 million with 7,113 outlets.
Retail Health (AHLL) EBITDA grew by 39% YoY to ₹476 million, reflecting improved profitability.

💡 Investors should take note of the significant margin expansion and the massive jump in PAT, which indicates strong operational efficiency. The continued growth in the digital health platform (Apollo 24|7) and the pharmacy network strengthens the company's long-term competitive position.

Apollo Hospitals Q3 FY26 PAT Surges 170% YoY to ₹4,219 Million

🟢 POSITIVE ⭐ 9/10

EARNINGS 📅 10 Feb 2026, 06:27 PM

Apollo Hospitals reported a robust performance for Q3 FY26, with consolidated revenue growing 17% YoY to ₹64,774 million. The company's Profit After Tax (PAT) saw a massive jump of 170% YoY, reaching ₹4,219 million, driven by strong operational efficiencies and growth across all business segments. Healthcare services remained the primary contributor with a 24.8% EBITDA margin, while the digital health and pharmacy segment (HealthCo) continued its growth trajectory with 20% revenue growth.

Consolidated PAT increased by 170% YoY to ₹4,219 million in Q3 FY26.
Healthcare Services revenue grew 14% YoY to ₹31,832 million with an EBITDA margin of 24.8%.
Average Revenue per IP Patient (ARPOB) stood at ₹180,917 with 67% occupancy across 10,325 beds.
Apollo HealthCo (Digital & Pharmacy) revenue rose 20% YoY to ₹28,274 million.
Retail Health (AHLL) EBITDA grew by 39% YoY to ₹476 million, showing improved profitability in diagnostics and clinics.

💡 The strong growth in PAT and steady margins in the core hospital business make this a positive update for long-term investors. Monitor the continued scaling and path to profitability of the Apollo 24|7 digital platform as it integrates further with the pharmacy business.

Apollo Hospitals Q3 FY26: PAT Surges 170% YoY to ₹5,023 Million; HealthCo Turns Profitable

🟢 POSITIVE ⭐ 9/10

EARNINGS 📅 10 Feb 2026, 06:27 PM

Apollo Hospitals Enterprise Limited reported a robust Q3 FY26 with consolidated revenue growing 15% YoY to ₹64,774 million. The company achieved a significant milestone as its Apollo HealthCo segment (Digital & Pharmacy) turned EBITDA positive at ₹1,279 million, compared to a loss of ₹1,027 million in the previous year. Net profit (PAT) saw a massive 170% jump to ₹5,023 million, driven by strong hospital margins and the digital turnaround. The core Healthcare Services division maintained a healthy 24.8% EBITDA margin with an average revenue per inpatient of ₹180,917.

Consolidated Revenue increased 15% YoY to ₹64,774 million in Q3 FY26.
Net Profit (PAT) grew by 170% YoY to ₹5,023 million.
Apollo HealthCo achieved EBITDA of ₹1,279 million, a sharp recovery from a ₹1,027 million loss in Q3 FY25.
Healthcare Services (Hospitals) reported 14% revenue growth and 18% EBITDA growth with 67% occupancy.
Pharmacy network expanded to 7,113 outlets with 46 million registered users on the Apollo 24|7 platform.

💡 The turnaround in the digital health and pharmacy segment is a major positive trigger for the stock's valuation. Investors should maintain a positive outlook given the strong hospital margins and the scaling of the omni-channel healthcare platform.

Apollo Hospitals Subsidiary Acquires Belenus Champion Hospitals for Rs 1,650 Million

🟢 POSITIVE ⭐ 8/10

M&A 📅 10 Feb 2026, 06:23 PM

Apollo Hospitals' subsidiary, Imperial Hospital and Research Centre Limited, has completed the 100% acquisition of Belenus Champion Hospitals in Bangalore for a total cost of Rs 1,650 million. The target company, which operates a 125-bed facility, reported a turnover of Rs 274.90 million in FY25. Apollo plans to invest a total of Rs 3,000 million to upgrade and expand the facility to 175 beds. The revamped multi-speciality hospital is scheduled to reopen by Q1 FY27, strengthening Apollo's footprint in the Bangalore healthcare market.

Acquired 100% stake in Belenus Champion Hospitals for a total consideration of Rs 1,650 million including liabilities.
Target company reported FY25 revenue of Rs 274.90 million compared to Rs 305.84 million in FY24.
Total project cost of Rs 3,000 million earmarked for acquisition and expansion to a 175-bed facility.
The hospital is currently being upgraded and is expected to be operational by Q1 FY27.
Acquisition executed through a 90% owned subsidiary, making Belenus a step-down subsidiary of Apollo Hospitals.

💡 Investors should monitor the progress of the facility upgrade as this acquisition strengthens Apollo's presence in the high-demand Bangalore market. The long-term value will depend on the successful turnaround and scaling of the 175-bed facility by FY27.

Apollo Hospitals Q3FY26 Standalone PAT up 12% YoY to ₹384 Cr; Declares ₹10 Interim Dividend

🟢 POSITIVE ⭐ 9/10

EARNINGS 📅 10 Feb 2026, 06:11 PM

Apollo Hospitals reported a robust performance for Q3FY26 with standalone revenue growing 15% YoY to ₹2,364 crore. Standalone EBITDA increased by 16% YoY to ₹594 crore, while Profit After Tax rose 12% to ₹384 crore, despite a one-time exceptional charge of ₹11.4 crore related to new labour codes. The Board has declared an interim dividend of ₹10 per share (200% of face value) with a record date of February 16, 2026. The company is also progressing with its strategic restructuring to demerge its pharmacy and digital health businesses.

Standalone Revenue from operations grew 15% YoY to ₹23,637 million compared to ₹20,548 million in Q3FY25.
Standalone EBITDA rose 16% YoY to ₹5,935 million from ₹5,118 million in the previous year.
Interim dividend of ₹10 per share declared; Record date fixed as February 16, 2026.
Profit After Tax (PAT) increased 12.3% YoY to ₹3,835 million despite an exceptional cost of ₹114 million.
Company has filed an application with NCLT for the demerger of its pharmacy distribution and digital health platform.

💡 Investors should take note of the steady double-digit growth across key financial metrics and the healthy dividend payout. The upcoming demerger of the pharmacy and digital health business remains a key monitorable for long-term value unlocking.

Apollo Hospitals Declares ₹10 Interim Dividend; Q3 PAT Rises 12% YoY to ₹3,835 Million

🟢 POSITIVE ⭐ 8/10

DIVIDEND 📅 10 Feb 2026, 06:03 PM

Apollo Hospitals has declared an interim dividend of ₹10 per share (200% of face value) for FY26, with the record date fixed for February 16, 2026. The company reported a 15% YoY growth in standalone revenue to ₹23,637 million for the quarter ended December 31, 2025. Standalone Profit After Tax (PAT) grew by 12% YoY to ₹3,835 million, even after accounting for a ₹114 million exceptional charge related to new labour codes. Additionally, the company is progressing with its composite scheme of arrangement for the demerger of its pharmacy and digital health businesses, currently awaiting NCLT approval.

Interim dividend of ₹10 per share (200% of FV) declared with a record date of February 16, 2026.
Standalone Revenue from operations increased 15% YoY to ₹23,637 million in Q3 FY26.
EBITDA grew 16% YoY to ₹5,935 million, maintaining healthy operational margins.
Net Profit (PAT) for the quarter stood at ₹3,835 million compared to ₹3,416 million in the previous year.
Exceptional item of ₹114 million recorded due to regulatory changes in Labour Codes affecting employee benefits.

💡 Investors seeking dividend income should ensure they hold the stock before the February 16 record date. Long-term investors should track the NCLT approval process for the pharmacy business demerger as it could unlock significant value.

View All APOLLOHOSP Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated revenue grew 15% YoY in FY25. Healthcare services segment, back-end pharmacy (AHL), and diagnostics/retail health were primary drivers. Pharmacy distribution grew 16% YoY. In Q2 FY26, Apollo HealthCo revenue reached INR 2,661 Cr (up 17% YoY) and Apollo Health & Lifestyle (AHLL) reached INR 474 Cr (up 17% YoY).

Geographic Revenue Split

Revenue is diversified across India: Tamil Nadu contributes 25%, Andhra Pradesh and Telangana 16%, and the Eastern region 23%. The remaining is spread across other geographies and metro/tier-2 cities.

Profitability Margins

Consolidated operating margins improved by 120 bps to 13.9% in FY25 from 12.7% in FY24. Healthcare services maintain robust margins of over 24%. Apollo HealthCo (AHL) margins improved to 1.8% in FY25 from negative levels in FY23/24. Post-demerger of AHL in FY28, margins are expected to reach 21-24%.

EBITDA Margin

Consolidated EBITDA margin is expected to sustain at 13.5-14% in FY26. Healthcare segment EBITDA is strong at 24%. Apollo HealthCo reported an EBITDA of INR 110 Cr in Q2 FY26, up 111.5% from INR 52 Cr in Q2 FY25.

Capital Expenditure

In FY25, total capital expenditure was INR 1,712.7 Cr, comprising INR 1,415.2 Cr for Hospitals, INR 143.7 Cr for AHLL, and INR 153.8 Cr for HealthCo. Planned expansion includes adding 3,500-4,300 beds over the next 3-4 years.

Credit Rating & Borrowing

Maintained 'CRISIL AA+/Stable/CRISIL A1+' rating. Total debt (including lease liabilities) stood at INR 5,389 Cr as of March 2025. The company availed new debt of INR 2,585.3 Cr in FY25 with a gearing ratio of 0.61x.

⚙️ Operational Drivers

Raw Materials

Material costs (medicines, surgical consumables, and medical supplies) represent 25.3% of total revenue.

Key Suppliers

Keimed Pvt Ltd is a key partner for pharmacy distribution infrastructure; other medical equipment and pharmaceutical vendors are used with renegotiated rates to improve unit economics.

Capacity Expansion

Current network includes 6,626 retail pharmacy stores. Planned expansion of 15 hospitals with a combined capacity of 4,300 beds in new and existing markets. Pharmacy segment aims to add at least 500 stores annually.

Raw Material Costs

Material costs are maintained at 25.3% of revenue, moving in line with revenue growth. Procurement strategies include leveraging Keimed's infrastructure and renegotiating vendor rates to reduce digital vertical losses by INR 30 Cr YoY in Q2 FY26.

Manufacturing Efficiency

Occupancy levels improved to 68% in FY25 from 65% in FY24. Average Revenue Per Occupied Bed (ARPOB) grew 5% YoY to INR 60,588. Inpatient (IP) discharges grew 7% to 604,250.

Logistics & Distribution

Pharmacy distribution business leverages a network of 6,626 stores and 96 distribution centers to ensure pan-India accessibility.

📈 Strategic Growth

Expected Growth Rate

15%

Growth Strategy

Growth will be achieved through the addition of 3,500-4,300 beds over 4 years, adding 500 pharmacy stores annually, and scaling the Apollo 24/7 digital platform (currently 44 million users). The company is also focusing on high-end surgical volumes in Centres of Excellence and increasing the mix of private label pharmacy products (currently 15.2% of revenue).

Products & Services

Inpatient and outpatient healthcare services, surgical procedures, pharmacy retail and distribution, diagnostic tests, and digital healthcare consultations via Apollo 24/7.

Brand Portfolio

Apollo Hospitals, Apollo 24/7, Apollo HealthCo, Apollo Health & Lifestyle (AHLL), Keimed, Apollo ESOP 2024.

New Products/Services

Expansion of private labels and generics in pharmacy (15.2% of revenue), digital therapeutics, and insurance monetization through the Apollo 24/7 platform.

Market Expansion

Expansion into Metro Tier 1 and Tier 2 cities with 15 new hospitals. Pharmacy expansion targeting 1,100+ cities and towns.

Market Share & Ranking

Largest private healthcare provider in the domestic Indian market; pharmacy business is more than 2x the size of the nearest competitor.

Strategic Alliances

Strategic investment of INR 725 Cr in Keimed Pvt Ltd by Apollo HealthCo to strengthen the distribution supply chain.

🌍 External Factors

Industry Trends

The industry is shifting toward omnichannel healthcare and digital integration. Apollo is positioning itself as a leader through Apollo 24/7, aiming for breakeven in the digital vertical within 6 quarters.

Competitive Landscape

Operates in a highly competitive market with other private hospital chains and unorganized retail pharmacies, but maintains leadership through scale and clinical excellence.

Competitive Moat

Durable moat through brand equity, the largest physical hospital network in India, JCI accreditations, and a pharmacy business with 2x the scale of competitors. Sustainability is high due to high switching costs in specialized tertiary care.

Macro Economic Sensitivity

Sensitive to domestic economic growth and healthcare spending; however, the essential nature of healthcare provides some resilience to inflation.

Consumer Behavior

Increasing preference for digital health services and home delivery of medicines, addressed by the 44 million user base on Apollo 24/7.

Geopolitical Risks

Minimal direct impact as operations are primarily domestic (India), though global supply chains for medical equipment may be affected.

⚖️ Regulatory & Governance

Industry Regulations

Subject to healthcare regulations, pollution norms for medical waste, and potential government pricing controls on essential medicines and medical procedures.

Environmental Compliance

The company ensures responsible disposal of medical waste and adheres to safety and skills upgradation training for all employees.

Taxation Policy Impact

Deferred tax liability stood at INR 458 Cr in FY25; no significant change from previous year.

⚠️ Risk Analysis

Key Uncertainties

The primary uncertainty is the continued cash burn of the Apollo 24/7 platform, which is expected to incur INR 350-400 Cr in annual spends over the medium term.

Geographic Concentration Risk

High concentration in South India, with Tamil Nadu, Andhra Pradesh, and Telangana accounting for 41% of the hospital footprint.

Third Party Dependencies

Significant dependency on Keimed for the back-end pharmacy supply chain and distribution.

Technology Obsolescence Risk

Risk of digital platform obsolescence; mitigated by continuous investment in Apollo 24/7 and recruitment of specialized medical consultants for advanced procedures.

Credit & Counterparty Risk

Receivables increased in FY25, contributing to a higher current ratio, but liquidity remains robust with over INR 1,900 Cr steady-state cash expected.